In the metastatic RCC currently available treatment options include tyrosine kinase inhibitors, anti-angiogenic drugs (sunitinib, sorafenib), mTOR inhibitors, nivolumab or immunotherapy. This evidence concerns the gene MTOR and renal cell carcinoma.